Europe Next Generation Sequencing Market Report by Products, Application, Technology, End User, Countries and Companies Analysis 2026-2034

Europe Next Generation Sequencing Market Size & Forecast 2026-2034

The Next Generation Sequencing (NGS) Market is expected to see steady growth in Europe, from US$ 2.43 billion in 2025 to US$ 13.94 billion by 2034, at a CAGR of 21.42% during 2026-2034. Supportive government initiatives, advancements in technologies of sequencing, declining costs of sequencing, and the expansion in the use of NGS in clinical diagnostics and pharmaceutical research are further helping to grow the market in Europe.

Outlook of Europe Next Generation Sequencing Market

NGS is an advanced technology for DNA and RNA sequencing that allows high-throughput, qualitative, and quantitative analysis of genetic material. It contrasts with the previous techniques of DNA sequencing, as NGS can handle millions of DNA fragments in parallel, while it can give results on whole-genome, exome, or a panel of genes with unprecedented accuracy and speed. Therefore, this represents an important technology in modern life sciences, enabling a wide range of applications, such as disease diagnosis, drug discovery, personalized medicine, oncology research, infectious disease monitoring, and agricultural genomics. Capable of generating large volumes of data in less time and at decreasing costs, NGS has definitely become a cornerstone in genomic research and clinical diagnostics.

Over the last decade, Next Generation Sequencing has gained phenomenal traction in Europe. In Europe, solid research infrastructure; well-established academic institutions; and continuously increasing government support for genomics and precision medicine initiatives are some of the reasons that enhance research studies.

The countries that hold a high level of profile in the adoption of NGS technologies are Germany, the United Kingdom, France, and the Netherlands, mainly due to cancer research, the diagnostics of rare diseases, and population genomics projects. Increasing applications of NGS in clinics and favorable reimbursement policy in some European nations have further accelerated adoption. Furthermore, the heightened awareness of genetic testing, improvements in next-generation sequencing platforms, and partnerships among research organizations, hospitals, and biotech companies spur the high acceptance of NGS across Europe.

Growth Driver in the Europe Next Generation Sequencing Market

Increasing Adoption of Precision Medicine in Europe

Precise medicine and personalized medicine are growing drivers of growth in the Europe Next Generation Sequencing market. NGS provides detailed genetic profiling that enables health care providers to offer tailored treatment against a patient's unique genetics. In Europe, an increase can be expected in the integration of genomic data into clinical decision-making within cancer treatments, rare diseases, and inherited disorders. Government-backed initiatives throughout Europe fund large-scale genome sequencing projects, hoping to improve both diagnosis and treatment outcomes. The pharmaceutical firms are making use of NGS to segregate the patent subgroups that are most likely to gain from the application of a particular therapy. Since the healthcare domain is shifting from a one-size-fits-all approach to targeted treatment approaches, demand for NGS technologies is increasing in clinical, research, and pharmaceutical applications in Europe. EP PerMed, the European Partnership for Personalised Medicine, was formally launched in Valencia in Oct 2023, during the high-level conference of the Spanish Presidency of the EU Council. This initiative reinforces precision medicine research across Europe, with 49 partners, supports innovation, knowledge transfer, and integration into healthcare.

Increasing Applications in Oncology and Diagnosis of Rare Diseases

Cancer is the second leading cause of death in Europe, accounting for 23% of all deaths in 2022, and is expected to become the primary cause of death by 2035. Therefore, NGS has played a crucial role in cancer genomics and the identification of rare disease conditions that will continue to drive market growth in Europe. The technology offers comprehensive mutation analysis, tumor profiling, and biomarker discovery that are critical for early detection and selection of therapies in cancer. With growing cancer incidence and increased awareness of rare genetic disorders in Europe, there has been rising adoption of NGS-based diagnostic tools in hospitals and research institutions. Many national healthcare systems in different European countries are including NGS in routine diagnostics, especially for hereditary cancers and pediatric genetic disorders.

Strong Research Infrastructure with Government Support

Europe has a well-established research ecosystem in academic institutions, biotechnology firms, and government-funded research programs. Genomics research, population sequencing initiatives, and translational medicine studies gain substantial investments in public and private investments. EU-funded programs foster cross-border collaboration and sharing of data, thereby accelerating the uptake of NGS. Research institutions increasingly apply NGS for studies in genomics, transcriptomics, epigenetics, and metagenomics. Genomics England is leading the Newborn Genome Programme with genome sequencing of infants for the early identification of genetic disorders. European Health and Digital Executive Agency HaDEA announces new funding opportunities under the 2025 EU4Health Work Programme. This new funding will enhance the preparedness and response of the European Union against future health emergencies.

Challenge in the Europe Next Generation Sequencing Market

High Sequencing and Data Analysis Costs

Despite declining sequencing costs, NGS remains a capital-intensive technology for many healthcare facilities and investigative institutions. It involves high upfront investments in sequencing instruments, consumables, and bioinformatics infrastructures. This poses significant challenges to smaller laboratories and hospitals. Moreover, data storage, analysis, and interpretation require a range of specialized talent and computationally intensive resources. Disparities within health funding across countries in Europe further curtail the adoption of technologies uniformly. Such financial issues are barriers to greater market penetration, particularly when underfunded healthcare systems are concerned.

Regulatory and Data Privacy Constraints

Regulatory policy frameworks in Europe, like the General Data Protection Regulation, provide challenges to NGS adoption. In sensitive genomic data handling, there are very strict data privacy and consent conditions, which include consent for data storage. This calls for greater administrative tasks and operational costs by the sequencing service providers. In addition, numerous and time-consuming regulatory approval processes of clinical diagnostics may further delay product commercialization. These factors add to the complexities faced by companies in expanding NGS-based diagnostics and services across multiple European markets.

Europe Next-Generation Sequencing Instruments Market

The Europe NGS instruments market is propelled by the growing requirements of research labs, clinical labs, and the pharma industry. Bench-top to high-throughput sequencing instruments are widely adopted in genomics research. Technological innovations are occurring rigorously. This leads to faster sequencing time, higher accuracy, and scale. Labs in Europe require versatile instruments capable of running various applications like oncology testing, infectious diseases testing, and whole genome sequencing. Though the high cost associated with the instruments is a hindrance, increased funding in research and clinical adoption are driving the market.

European Next Generation Sequencing Services Market

NGS service providers are becoming popular in Europe due to the outsourcing trend in research institutions and hospitals. Sequencing service providers provide turnkey solutions, from preparing a sample to generating reports. This approach lowers the capital expenditure requirements of the buyer. The pharmaceutical and biotech industries increasingly wish to access the services of third-party NGS service providers. The growing complexity of genomic information and the need for sophisticated bioinformatics support have driven the growth in this market.

Europe Next Generation Sequencing Diagnostics Market

Next-generation sequencing-based diagnostics are revolutionizing healthcare in Europe. These applications range from cancer diagnosis, prenatal screening, infectious disease testing, and screening for rare genetic disorders. A considerable number of healthcare settings in Europe are adopting next-generation sequencing into their mainstream diagnostics framework because next-generation sequencing helps provide improved precision and complete information about the genes. Greater awareness among both healthcare providers and patients, as well as supportive government policies regarding reimbursements in some regions, is propelling the market ahead.

Europe Drug Discovery Next Generation Sequencing Market

NGS is finding applications in the discovery process for identifying targets, biomarkers, and genetic variations for drug response. The use of NGS is increasing in the European pharma industry for tasks such as genomic profiling, companion diagnostics, and precision drug development. NGS improves R&D productivity by saving time and money associated with conventional approaches. Investment in the biopharma R&D area is on the rise in the European market, increasing the demand for NGS.

Europe Next Generation Sequencing by Synthesis Market

The European market for Sequencing by Synthesis (SBS) technology has been the most widely used NGS technology in the European market because of the high accuracy levels that the technology has to offer. The SBS technique has found widespread applications in the fields of whole genome, targeted, and RNA sequencing. Researchers and scientists in the European region highly esteem the technique for the accuracy of the data it produces. Advances in the SBS chemistry technology have played a significant part in the widespread adoption of the technology in the European market.

Europe Next-Generation Ion Semiconductor Sequencing Market

Ion semiconductor sequencing is increasingly being adopted in Europe for targeted sequencing and diagnostic purposes. The technology has the advantage of faster run times and easier operation when compared to some traditional platforms. It has the potential for adoption, especially for medium-scale labs, and the need for fast genetic and infectious disease testing is also contributing to its adoption, albeit to a lesser extent than the adoption of sequencing by synthesis.

Europe Next Generation Sequencing Hospitals and Clinics Market

European hospitals and clinics are increasingly adopting NGS technology for clinical diagnostics and personalized medicine decisions. Oncology departments have been primary adoption domains for NGS technology, which is utilized for tumor profiling and cancer treatments. The adoption of NGS technology in hospitals will help in better diagnostics and improved patient outcomes. Government and national genomics projects are further promoting NGS technology adoption in clinical environments.

Germany Next-Generation Sequencing Market

Germany leads the European market for NGS, thanks to robust research organizations and sophisticated medical infrastructure. High levels of adoption of NGS technology are seen in Germany for cancer, rare diseases, and pharmaceutical research. Major investments are being made in Germany to fuel advancements. QIAGEN has announced that there are plans to launch three sample preparation instruments during 2025 and 2026 to enable and enhance its current portfolio of instruments for automated sample preparation.

Next-Generation Sequencing Market Research -France Report

The French genomics research infrastructure is well established, and adoption of NGS in diagnostics is on the increase. National programs for precision medicine facilitate growth of the market. NGS is progressively being incorporated in cancer diagnostics and population genomics studies in France. February 2025, Devyser launches Devyser Thalassemia v2, a next-generation sequencing (NGS) platform aimed at further simplifying genetic analysis. This new technology will facilitate wider genotyping of thalassemia and will be more precise in identifying structural variations, hence saving time and providing faster and better research outcomes globally.

United Kingdom Next Generation Sequencing Market

The United Kingdom is at the lead in the adoption rate of NGS, thanks to the scale of genome projects and the NHS. The UK embraces the use of NGS in the diagnosis of rare diseases, cancer, and infectious diseases. There have been favorable conditions in the UK regarding innovating and funding to continue supporting the growing market. In August 2023, Almac Diagnostic Services, operating within the Almac Group, made the announcement to upgrade their NGS offering to BioPharma partners, considering the acquisition and installation of the first Illumina NovaSeqTM X Plus in Northern Ireland and the entire island of Ireland.

Russia Next Generation Sequencing Market

The NGS market in Russia is emerging gradually with growing investments in biotechnology. The major driving force for the adoption of NGS in the country is academic research and the study of infectious diseases. Although the growth of the NGS market is low in Russia compared to other European countries, growing attempts to modernize the healthcare infrastructure in the region open up new possibilities for the future. August 2025, Russia is going to greatly enlarge its national genetic data base by 2030, following a new decree recently approved by the Russian government. According to the plans, the size of the existing genetic data base is going to be increased by 35 times, reaching a total of 35 petabytes by the year 2030. The implementation of the new project is going to be followed by a new legislative act called the Strategic Direction in the Field of Digital Transformation of Science and Education, recently approved by the Russian government in the middle of July.

Market Segmentations

Products

• Instruments
• Reagents & Consumables
• Services

Application

• Diagnostics
• Agriculture and Animal Research
• Drug Discovery
• Personalized Medicine and Genetic Screening
• Others

Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single Molecule Read Time Sequencing
• Nanopore Sequencing
• Others

End User

• Academic and Clinical Research Centers
• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Others

Countries

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences of California
• QIAGEN N.V
• Roche
• Bio-Rad Laboratories, Inc.
• Takara Bio Inc.
• Hamilton Company
• Geneious
• BioMerieux SA